Medicated weight-loss treatments have soared over recent months, reaching an estimated 1.5 million users in the UK in March 2025, according to data shared by IQVIA.
The UK weight management market has seen an average monthly volume growth of 24.6% since October 2024, Chris Pilsbury, senior director at market intelligence company IQVIA, revealed today at the Sigma 2025 conference in Baku, Azerbaijan.
He also shared that since October 2024, there has been a 56% growth in the amount that people in the UK spend on private access to medicines – from £503m to £784m in October 2025.
Related Article: CPhO: ‘Ambition’ to explore weight-loss meds through non-GP routes
Around £210m of that spending related to weight management medication, IQVIA revealed.
He suggested there was an estimated 1.5 million UK citizens receiving ongoing weight-loss management medication in March 2025 alone – with some 1,527,000 packs supplied.
The ‘significant growth’ was largely driven by online providers that account for around 80% of purchases, said Mr Pilsbury.
But Mr Pilsbury stressed that there was still a £72m or 17% increase in other private treatments once weight-loss medication was excluded.
The biggest area for growth outside of obesity medication was anti-asthma and COPD, IQVIA revealed.
Related Article: CPE 'open to discussing' NHS weight-loss jabs through pharmacies
Other areas of growth included phsycoanaleptics, hormone therapies, central nervous system drugs and oncology.
Mr Pilsbruy said that it was an ‘exciting time for innovation’ in drug development, including 169 new assets from 70 companies in the obesity pipeline.
He suggested new therapies could provide ‘lots of opportunities’ for community pharmacy.
And he suggested that weight-loss medications were driving increased use of distance-selling pharmacies.
Related Article: Pharmacies told to ‘immediately review’ adverts for weight-loss meds
Earlier this month, Community Pharmacy England (CPE) said it was 'open to discussing' how weight-loss injections could be delivered through community pharmacies on the NHS, following rumoured plans reported in the national media.
IQVIA co-authored the recent economic analysis of community pharmacy, alongside Frontier economics.
Keep your clinical knowledge up to date with The Pharmacist
Extend your learning and record your learning outcomes
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.